tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Peterson LB et al. A tacrolimus-related immunosuppressant with biochemical properties distinct from those of tacrolimus. 1998 Transplantation pmid:9448137
Dumont FJ et al. A tacrolimus-related immunosuppressant with reduced toxicity. 1998 Transplantation pmid:9448138
Mieles L et al. Interaction between FK506 and clotrimazole in a liver transplant recipient. 1991 Transplantation pmid:1721250
Connor A et al. Generic tacrolimus in renal transplantation: trough blood concentration as a surrogate for drug exposure. 2012 Transplantation pmid:23318306
Roth D et al. A prospective study of hepatitis C virus infection in renal allograft recipients. 1996 Transplantation pmid:8623154
Plock JA et al. Adipose- and Bone Marrow-Derived Mesenchymal Stem Cells Prolong Graft Survival in Vascularized Composite Allotransplantation. 2015 Transplantation pmid:26102613
Stevens RB et al. Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report. 2008 Transplantation pmid:18497677
Gurk-Turner C et al. Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients. 2008 Transplantation pmid:18497682
Rolles K et al. A pilot study of immunosuppressive monotherapy in liver transplantation: tacrolimus versus microemulsified cyclosporin. 1999 Transplantation pmid:10551650
Pirsch JD Cytomegalovirus infection and posttransplant lymphoproliferative disease in renal transplant recipients: results of the U.S. multicenter FK506 Kidney Transplant Study Group. 1999 Transplantation pmid:10551653
Sugitani A et al. En bloc pancreas and kidney transplantation in a patient with limited vascular access. 1997 Transplantation pmid:9197366
Arns W et al. Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial. 2017 Transplantation pmid:28658202
Taber DJ et al. Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation. 2017 Transplantation pmid:28658199
Diémé B et al. Assessing the metabolic effects of calcineurin inhibitors in renal transplant recipients by urine metabolic profiling. 2014 Transplantation pmid:24598938
Mañez R et al. Fluconazole therapy in transplant recipients receiving FK506. 1994 Transplantation pmid:7515201
Jordan ML et al. Results of pancreas transplantation after steroid withdrawal under tacrolimus immunosuppression. 2000 Transplantation pmid:10670637
Hirose R et al. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. 2000 Transplantation pmid:10670644
Furukawa H et al. The effect of bile duct ligation and bile diversion on FK506 pharmacokinetics in dogs. 1992 Transplantation pmid:1373531
Sakr M et al. Cytomegalovirus infection of the upper gastrointestinal tract following liver transplantation--incidence, location, and severity in cyclosporine- and FK506-treated patients. 1992 Transplantation pmid:1373535
Han DH et al. Effect of sirolimus on calcineurin inhibitor-induced nephrotoxicity using renal expression of KLOTHO, an antiaging gene. 2010 Transplantation pmid:20562737
Hirano Y et al. Morphological and functional changes of islets of Langerhans in FK506-treated rats. 1992 Transplantation pmid:1373536
Ashokkumar C et al. Allospecific CD154+ T-cytotoxic memory cells identify recipients experiencing acute cellular rejection after renal transplantation. 2011 Transplantation pmid:21747326
Kim CD et al. Metabonomic analysis of serum metabolites in kidney transplant recipients with cyclosporine A- or tacrolimus-based immunosuppression. 2010 Transplantation pmid:20842074
Berenguer M et al. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. 2010 Transplantation pmid:21068701
Cosio FG et al. Comparison of low versus high tacrolimus levels in kidney transplantation: assessment of efficacy by protocol biopsies. 2007 Transplantation pmid:17318073
Budde K et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. 2007 Transplantation pmid:17318074
Sindhi R et al. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. 2001 Transplantation pmid:11571449
Murase N et al. Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. 1990 Transplantation pmid:1696405
Timmermann W et al. Videomicroscopic imaging of graft mucosa for monitoring immunosuppressive therapy after small intestinal transplantation in rats. 1999 Transplantation pmid:10401762
Stifft F et al. Lower variability in 24-hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation. 2014 Transplantation pmid:24686426
Sampaio MS et al. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients. 2012 Transplantation pmid:22129761
Jain A et al. Long-term follow-up after liver transplantation for alcoholic liver disease under tacrolimus. 2000 Transplantation pmid:11087149
Shibutani S et al. Effects of immunosuppressants on induction of regulatory cells after intratracheal delivery of alloantigen. 2005 Transplantation pmid:15849542
Tzakis AG et al. Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation. 2003 Transplantation pmid:12792506
Peloso LJ et al. The serum concentration of tacrolimus after ingesting omeprazole: a pilot study. 2014 Transplantation pmid:25221905
Koenen HJ et al. Superior T-cell suppression by rapamycin and FK506 over rapamycin and cyclosporine A because of abrogated cytotoxic T-lymphocyte induction, impaired memory responses, and persistent apoptosis. 2003 Transplantation pmid:12792519
Tory R et al. Tacrolimus-induced elevation in plasma triglyceride concentrations after administration to renal transplant patients is partially due to a decrease in lipoprotein lipase activity and plasma concentrations. 2009 Transplantation pmid:19584682
Jain A et al. Pharmacokinetics of tacrolimus in living donor liver transplant and deceased donor liver transplant recipients. 2008 Transplantation pmid:18347534
Weiler N et al. Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial. 2010 Transplantation pmid:21048536
First MR Strategies to minimize immunological and nonimmunological risk factors in the renal transplant population. 2001 Transplantation pmid:11585240
Koomans HA and Ligtenberg G Mechanisms and consequences of arterial hypertension after renal transplantation. 2001 Transplantation pmid:11585243
Tarumi K et al. CTLA4IgG treatment induces long-term acceptance of rat small bowel allografts. 1999 Transplantation pmid:10071020
Alhamad T et al. Targeting High Calcineurin Inhibitor Levels After Acute Rejection With Less Tremor: A New Strategy. 2017 Transplantation pmid:28422926
Trimarchi HM et al. FK506-associated thrombotic microangiopathy: report of two cases and review of the literature. 1999 Transplantation pmid:10071024
Robertsen I et al. Use of generic tacrolimus in elderly renal transplant recipients: precaution is needed. 2015 Transplantation pmid:25148382
Sokal EM et al. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. 1997 Transplantation pmid:9392308
Königsrainer A et al. Nonocclusive segmental mesenteric ischemia after combined pancreas kidney transplantation: mycophenolate mofetil as an etiological factor? 2000 Transplantation pmid:10972233
Bozorgzadeh A et al. Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus. 2004 Transplantation pmid:15087773
Sofi AA et al. Bullous pemphigoid associated with acute renal allograft rejection. 2010 Transplantation pmid:20145531
Benigni A et al. The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance. 1992 Transplantation pmid:1279848
Gaber AO et al. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial. 2008 Transplantation pmid:19005398
Luan FL et al. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. 2002 Transplantation pmid:12042641
Hoogduijn MJ et al. Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin. 2008 Transplantation pmid:19005411
McDevitt-Potter LM et al. A multicenter experience with generic tacrolimus conversion. 2011 Transplantation pmid:21788920
Roth D et al. Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients. 1998 Transplantation pmid:9458023
Hadley S et al. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. 1995 Transplantation pmid:7535482
Gill JS et al. Screening for de novo anti-human leukocyte antigen antibodies in nonsensitized kidney transplant recipients does not predict acute rejection. 2010 Transplantation pmid:20098280
Wallia A et al. Posttransplant hyperglycemia is associated with increased risk of liver allograft rejection. 2010 Transplantation pmid:20098286
Alessiani M et al. Combined immunosuppressive therapy with tacrolimus and mycophenolate mofetil for small bowel transplantation in pigs. 1996 Transplantation pmid:8830816
Zhao W et al. Pharmacokinetic interaction between tacrolimus and amlodipine in a renal transplant child. 2012 Transplantation pmid:22450597
Pascual J et al. Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation. 2009 Transplantation pmid:19136902
Jacobson PA et al. Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium. 2012 Transplantation pmid:22334041
Schneeberger S et al. Cytomegalovirus-related complications in human hand transplantation. 2005 Transplantation pmid:16123716
Ciancio G et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. 2005 Transplantation pmid:16123718
Vossen M et al. Bone quality in swine composite tissue allografts: effects of combination immunotherapy. 2005 Transplantation pmid:16123723
Miyazawa H et al. Hamster to rat kidney xenotransplantation. Effects of FK 506, cyclophosphamide, organ perfusion, and complement inhibition. 1995 Transplantation pmid:7537396
Irish W et al. Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen. 2003 Transplantation pmid:14688516
Furlan V et al. Interactions between FK506 and rifampicin or erythromycin in pediatric liver recipients. 1995 Transplantation pmid:7537398
Akst LM et al. Induction of tolerance in a rat model of laryngeal transplantation. 2003 Transplantation pmid:14688529
Lauria MW et al. Metabolic long-term follow-up of functioning simultaneous pancreas-kidney transplantation versus pancreas transplantation alone: insights and limitations. 2010 Transplantation pmid:20061923
Mañez R et al. Anomalous pattern of IgG antibody response to primary cytomegalovirus infection after solid organ retransplantation. 1995 Transplantation pmid:7537400
Fujii Y et al. Effect of a novel immunosuppressive agent, FK506, on mitogen-induced inositol phospholipid degradation in rat thymocytes. 1989 Transplantation pmid:2472025
Chisholm MA et al. Coadministration of tacrolimus with anti-acid drugs. 2003 Transplantation pmid:12973105
Koch R et al. Cyclosporine A-induced achalasia-like esophageal motility disorder in a liver transplant recipient: successful conversion to tacrolimus. 2003 Transplantation pmid:12973123
Mourad M et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. 2005 Transplantation pmid:16249748
McDiarmid SV et al. Factors affecting growth after pediatric liver transplantation. 1999 Transplantation pmid:10030286
Shapiro R et al. A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. 1999 Transplantation pmid:10030287
Paty BW et al. Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets. 2002 Transplantation pmid:11884930
Dell'Antonio G and Randhawa PS "Striped" pattern of medullary ray fibrosis in allograft biopsies from kidney transplant recipients maintained on tacrolimus. 1999 Transplantation pmid:10030300
Ericzon BG et al. Secretion and composition of bile after human liver transplantation: studies on the effects of cyclosporine and tacrolimus. 1997 Transplantation pmid:9000664
Kelly PA et al. Ciprofloxacin does not block the antiproliferative effect of tacrolimus. 1997 Transplantation pmid:9000686
Ueda M et al. A proposal of FK506 optimal dosing in living related liver transplantations. 1995 Transplantation pmid:7544035
Boots JM et al. Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. 2002 Transplantation pmid:12499885
Beckebaum S et al. Predictive factors of outcome in patients transplanted for hepatitis B. 2009 Transplantation pmid:19300191
Higgins R et al. Rises and falls in donor-specific and third-party HLA antibody levels after antibody incompatible transplantation. 2009 Transplantation pmid:19300192
Pascual J et al. Authors' reply: cyclosporine A versus tacrolimus in steroid withdrawal strategies. 2011 Transplantation pmid:21336083
Steiner RW Steroid withdrawal in kidney transplantation: the subgroup fallacy. 2011 Transplantation pmid:21336084
MacDonald A Improving tolerability of immunosuppressive regimens. 2001 Transplantation pmid:11833142
Wang K et al. Transplantation of infantile bladder in rats: an alternative procedure for bladder augmentation. 2001 Transplantation pmid:11213059
Molleví DG et al. Heart and liver xenotransplantation under low-dose tacrolimus: graft survival after withdrawal of immunosuppression. 2001 Transplantation pmid:11213062
Paolillo JA et al. Posttransplant diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression. 2001 Transplantation pmid:11213069
Schvarcz R et al. Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV). 2000 Transplantation pmid:10852623
Lake JR et al. The impact of immunosuppressive regimens on the cost of liver transplantation--results from the U.S. FK506 multicenter trial. 1995 Transplantation pmid:7482713
Mathew A et al. Reversal of steroid-resistant rejection in renal allograft recipients using FK506. 1995 Transplantation pmid:7482730
Stephen M et al. Immunosuppressive activity, lymphocyte subset analysis, and acute toxicity of FK-506 in the rat. A comparative and combination study with cyclosporine. 1989 Transplantation pmid:2463701
Macphee IA et al. Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. 2005 Transplantation pmid:15729180
Shibasaki S et al. Immunosuppressive effects of DTCM-G, a novel inhibitor of the mTOR downstream signaling pathway. 2013 Transplantation pmid:23269193
Fuchinoue S et al. Kidney transplantation after liver transplantation from the same donor: four cases of successful steroid withdrawal. 2002 Transplantation pmid:11923698
Lauzurica R et al. Tacrolimus-associated severe bilateral corneal ulcer after renal transplantation. 2002 Transplantation pmid:11923710
Mayer AD et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. 1997 Transplantation pmid:9275110